Send to:

Choose Destination
See comment in PubMed Commons below
Hematol Oncol Clin North Am. 2004 Jun;18(3):641-56, ix.

Clinical resistance to imatinib: mechanisms and implications.

Author information

  • 1III. Medizinische Klinik, Fakultät für Klinische Medizin Mannheim, Universität Heidelberg, Wiesbadener Strasse 7-11, 68305 Mannheim, Germany.


Although responses to imatinib in chronic phase chronic myelogenous leukemia have been durable in most cases, most patients in advanced disease develop resistance and relapse after a short duration of therapy. The mechanisms of drug resistance are diverse, but in most cases, mutations are found at the time of resistance that change amino acids within the kinase domain of BCR-ABL. Cytogenetic and molecular analyses at the time of resistance are suggested to guide therapy.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk